secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001193125-23-136095
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio enters $450M ATM equity offering program; terminates prior $500M facility
--------------------------------------------------------------------------------

- ATM allows sale of up to $450M in common stock at Company's discretion; 3% commission to agents.
- Prior ATM with Jefferies and SVB Securities terminated effective May 3, 2023.
- Goldman Sachs and SVB Securities serve as sales agents on a best-efforts basis.
- Shares may be sold as 'at the market' offerings on Nasdaq or other trading markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000119312523136095/0001193125-23-136095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000119312523136095/d336282d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-136095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer